Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
13F holders, Q3 2025
Institutional positions in Akero Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
AKRO is no longer listed, so this page shows Q3 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 265
- +10 vs. Q2 2025
- Shares held
- 91.5M
- −666.0K (−0.7%) vs. Q2 2025
- Total value
- $4.34B
- −$573.4M (−11.7%) vs. Q2 2025
- New holders
- 46
- 75 more added
- Sold out
- 36
- 92 more reduced
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AKRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 5 | $533.0K |
| Q3 2025 | 265 | $4.34B |
| Q2 2025 | 257 | $4.92B |
| Q1 2025 | 240 | $3.50B |
| Q4 2024 | 191 | $2.06B |
| Q3 2024 | 168 | $2.09B |
| Q2 2024 | 153 | $1.68B |
| Q1 2024 | 173 | $1.85B |
| Q4 2023 | 157 | $1.38B |
| Q3 2023 | 181 | $2.90B |
| Q2 2023 | 157 | $2.63B |
| Q1 2023 | 156 | $1.84B |
| Q4 2022 | 162 | $2.66B |
| Q3 2022 | 146 | $1.59B |
| Q2 2022 | 113 | $329.6M |
| Q1 2022 | 103 | $499.2M |
| Q4 2021 | 97 | $746.8M |
| Q3 2021 | 103 | $626.0M |
| Q2 2021 | 97 | $684.2M |
| Q1 2021 | 109 | $913.6M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Akero Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Twin Peaks Wealth Advisors, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |